Roche Acquires Tensha Therapeutics for $535,000,000
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=064a2ea1-14db-4543-a154-7541eedb16b6 - Date
1/11/2016 - Company Name
Tensha Therapeutics - Mailing Address
55 Cambridge Parkway Cambridge, MA 02142 USA - Company Description
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. - Website
http://www.tenshatherapeutics.com - Transaction Type
M&A - Transaction Amount
$535,000,000 - Transaction Round
- Proceeds Purposes
- M&A Terms
Under the terms of the agreement, Tensha’s shareholders will receive an upfront cash payment of $115 million, plus additional contingent payments of up to $420 million based on the achievement of certain predetermined clinical and regulatory milestones.
